Merck, NDAC Chair Neill Cross Paths Again For Oxytrol Switch Meeting
This article was originally published in The Tan Sheet
Executive Summary
Nonprescription Drugs Advisory Committee member Richard Neill in 2007 praised Merck’s Rx-to-OTC application for Mevacor while voting against the statin switch. On Nov. 9, Merck will try to convince now-chairman Neill and the rest of NDAC that overactive bladder drug Oxytrol can safely be sold OTC.
You may also be interested in...
Anthrax MedKit Initiative Could Learn From OTC Studies – NDAC
FDA’s Nonprescription Drugs Advisory Committee recommends the HHS sponsors of an antibiotic MedKit take lessons from OTC drug development. But many advisory panel members at an April 2 meeting did not see clear benefits of allowing home stockpiling of doxycycline to treat anthrax.
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin
Prilosec 1 Self-Selected Correctly By 81% Of Actual Use Study Participants
Eighty-one percent of 866 participants in the Prilosec 1 actual use study correctly chose the heartburn medication as appropriate for them to use, Procter & Gamble OTC Drug Development Director Douglas Bierer, PhD, reported (See chart: "1The Prilosec 1 NDA: Take 2")